Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats - PubMed (original) (raw)
Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats
Marina C Muñoz et al. J Hypertens. 2009 Dec.
Abstract
Background: Angiotensin II (Ang II) has been shown to contribute to the pathogenesis of hypertension and insulin resistance. In addition, administration of selective Ang II type-1 receptor blockers has been shown to improve insulin sensitivity. However, only a few studies have addressed the molecular mechanisms involved in this association.
Objective and design: The current study was undertaken to determine whether an Ang II receptor blocker (irbesartan) is effective in improving insulin resistance in adipose tissue from obese Zucker rats, a model of metabolic syndrome.
Methods: Ten-week-old male obese Zucker rats (fa/fa) were treated daily with either vehicle or 50 mg/kg irbesartan for 6 months, and their age-matched lean (+/?) (lean Zucker rats) was used as a control. We determined systolic blood pressure (SBP), together with plasma levels of insulin, triglycerides, cholesterol and glucose. In addition, we evaluated insulin signaling through the insulin receptor/insulin receptor substrate-1/phosphatidylinositol 3 kinase/Akt/glucose transporter 4 pathway as well as the inflammatory status of adipose tissue.
Results: Obese Zucker rats displayed hyperglycemia, hypertriglyceridemia, hyperinsulinemia and hypercholesterolemia and increased SBP together with decreased activation of insulin signaling through the insulin receptor/insulin receptor substrate-1/phosphatidylinositol 3 kinase/Akt pathway in adipose tissue as well as increased adipocytes size, macrophage infiltration and augmented levels of inflammatory mediators such tumor necrosis factor-alpha, monocyte chemoattractant protein-1 and Ang II. Chronic irbesartan treatment resulted in an improvement of all alterations.
Conclusion: The present study provides substantial information that demonstrates that long-term selective Ang II blockade ameliorates insulin resistance in adipose tissue from a model of metabolic syndrome via a mechanism that could involve the modulation of insulin signaling.
Similar articles
- Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.
Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Muñoz MC, et al. J Hypertens. 2006 Aug;24(8):1607-17. doi: 10.1097/01.hjh.0000239297.63377.3f. J Hypertens. 2006. PMID: 16877964 - Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Janiak P, Bidouard JP, Cadrouvele C, Poirier B, Gouraud L, Grataloup Y, Pierre F, Bruneval P, O'Connor SE, Herbert JM. Janiak P, et al. Eur J Pharmacol. 2006 Mar 18;534(1-3):271-9. doi: 10.1016/j.ejphar.2006.01.032. Epub 2006 Mar 6. Eur J Pharmacol. 2006. PMID: 16516882 - Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats.
Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda F, Capuano A, D'Amico M. Di Filippo C, et al. Obes Res. 2005 Nov;13(11):1909-14. doi: 10.1038/oby.2005.235. Obes Res. 2005. PMID: 16339122 - Oxidized HDL is a potent inducer of adipogenesis and causes activation of the Ang-II and 20-HETE systems in human obese females.
Peterson SJ, Vanella L, Gotlinger K, Jiang H, Singh SP, Sodhi K, Maher E, O'Hanlon K, Shapiro JI, Abraham NG. Peterson SJ, et al. Prostaglandins Other Lipid Mediat. 2016 Mar;123:68-77. doi: 10.1016/j.prostaglandins.2016.04.004. Epub 2016 May 11. Prostaglandins Other Lipid Mediat. 2016. PMID: 27179555 Review. - Role of angiotensin II receptor blockers in atherosclerotic plaque stability.
Cipollone F, Fazia ML, Mezzetti A. Cipollone F, et al. Expert Opin Pharmacother. 2006 Feb;7(3):277-85. doi: 10.1517/14656566.7.3.277. Expert Opin Pharmacother. 2006. PMID: 16448322 Review.
Cited by
- The Role of Local Angiotensin II/Angiotensin Type 1-receptor Mechanisms in Adipose Tissue Dysfunction to Promote Pancreatic Cancer.
Khodashahi R, Beiraghdar F, Ferns GA, Ashrafzadeh K, Aliakbarian M, Arjmand MH. Khodashahi R, et al. Curr Cancer Drug Targets. 2024;24(12):1187-1194. doi: 10.2174/0115680096281059240103154836. Curr Cancer Drug Targets. 2024. PMID: 38347780 Review. - Acute In Vivo Administration of Compound 21 Stimulates Akt and ERK1/2 Phosphorylation in Mouse Heart and Adipose Tissue.
Quiroga DT, Narvaéz Pardo JA, Zubiría MG, Barrales B, Muñoz MC, Giovambattista A, Dominici FP. Quiroga DT, et al. Int J Mol Sci. 2023 Nov 28;24(23):16839. doi: 10.3390/ijms242316839. Int J Mol Sci. 2023. PMID: 38069161 Free PMC article. - Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
Chou CL, Li CH, Fang TC. Chou CL, et al. Nutrients. 2022 Sep 12;14(18):3759. doi: 10.3390/nu14183759. Nutrients. 2022. PMID: 36145135 Free PMC article. - Chronic AT1 blockade improves hyperglycemia by decreasing adipocyte inflammation and decreasing hepatic PCK1 and G6PC1 expression in obese rats.
Rodriguez R, Lee AY, Godoy-Lugo JA, Martinez B, Ohsaki H, Nakano D, Parkes DG, Nishiyama A, Vázquez-Medina JP, Ortiz RM. Rodriguez R, et al. Am J Physiol Endocrinol Metab. 2021 Nov 1;321(5):E714-E727. doi: 10.1152/ajpendo.00584.2020. Epub 2021 Oct 18. Am J Physiol Endocrinol Metab. 2021. PMID: 34658252 Free PMC article. - Activation of AT2 receptors prevents diabetic complications in female db/db mice by NO-mediated mechanisms.
Dominici FP, Veiras LC, Shen JZY, Bernstein EA, Quiroga DT, Steckelings UM, Bernstein KE, Giani JF. Dominici FP, et al. Br J Pharmacol. 2020 Oct;177(20):4766-4781. doi: 10.1111/bph.15241. Epub 2020 Sep 13. Br J Pharmacol. 2020. PMID: 32851652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous